VP-102 Tolerability Evaluated by Concomitant Analgesic Medication Usage in Two Phase 3 Trials for Molluscum Contagiosum

Elaine Siegfried MD1, Lawrence F. Eichenfield MD2, Pearl C. Kwong MD, PhD3, Jeffrey Sugarman MD4, Susan Cutler DMD5, Gary Goldenberg MD5,6

INTRODUCTION
• Drug tolerability is the degree to which a patient can tolerate a drug’s adverse effects.
• VP-102, a drug-device combination product containing cantharidin (0.7%), a vesicant, is approved for treatment of molluscum contagiosum (molluscum) in patients aged 2 and older.
• Local skin reactions (LSRs) are expected, including pain.
• In Phase 3 trials, 97% of LSRs were mild to moderate.
• The discontinuation rate due to an adverse reaction was 2.3%:0.5% (drug:vehicle) in treated subjects.

METHODS
• VP-102 or vehicle was applied to all baseline and new lesions once every 21 days until complete clearance, or up to a maximum of 4 applications.
• Acetaminophen or ibuprofen were permitted for application site pain and/or other Adverse Reactions.

RESULTS: EFFICACY

% of Subjects with Pain and Analgesic Use

RESULTS: SAFETY

• Analgesic usage for AEs other than LSR pain included 6% (19/311) for application site vesicles.
• There were no treatment-related SAEs reported.

CONCLUSIONS
• In this largely pediatric population, VP-102 was well-tolerated, with a short duration of elective analgesic use.

Disclosures
The studies were sponsored by Verrica Pharmaceuticals Inc. Editorial support was provided by Verant Learning Solutions and funded by Verrica Pharmaceuticals Inc. The authors have received the following from Verrica Pharmaceuticals: E. Siegfried: H, C, L. Eichenfield: H, C, S; P. Kwong: H, C; J. Sugarman: H, C; S. Cutler: H; G. Goldenberg: E; H=honoria; C=<clinical funds; S=stocks; E=employee.